QianJun Li, JingJing Zhao, RuiChao Yan, QiJian Gao, Yao Zhen, Xue Li, Ying Liang, ShiHao Min, LiJuan Yang
WeChat mini program in laboratory biosafety education among medical students at Guangzhou Medical University: a mixed method study of feasibility and usability
BMC medical education
motor neuron disease progressive fatal neurodegenerative disease cure acceptance commitment therapy act psychological therapy incorporating acceptance mindfulness behaviour change techniques aimed evaluate effectiveness act plus usual care compared usual care alone improving quality life people motor neuron disease conducted parallel multicentre twoarm randomised controlled trial 16 uk motor neuron disease care centres clinics eligible participants aged 18 years older diagnosis definite laboratorysupported probable clinically probable possible familial sporadic amyotrophic lateral sclerosis progressive muscular atrophy primary lateral sclerosis met world federation neurologys el escorial diagnostic criteria participants randomly assigned 11 receive eight sessions act adapted people motor neuron disease plus usual care usual care alone webbased system stratified site participants followed 6 months 9 months postrandomisation outcome assessors trial statisticians masked treatment allocation primary outcome quality life using mcgill quality life questionnairerevised mqolr 6 months postrandomisation primary analyses multilevel modelling modified intention treat among participants available data trial preregistered isrctn registry isrctn12655391 sept 18 2019 aug 31 2022 435 people motor neuron disease approached study 206 47 assessed eligibility 191 recruited 97 51 participants randomly assigned act plus usual care 94 49 assigned usual care alone 80 42 191 participants female 111 58 male mean age 631 years sd 110 155 81 participants primary outcome data 6 months postrandomisation controlling baseline scores age sex therapist clustering act plus usual care superior usual care alone quality life 6 months adjusted mean difference mqolr 066 95 ci 022110 d046 016077 p00031 moderate effect sizes clinically meaningful 75 adverse events reported 38 serious adverse events deemed associated intervention act plus usual care clinically effective maintaining improving quality life people motor neuron disease evidence emerges confirming findings healthcare providers consider access act adapted specific needs people motor neuron disease could provided within motor neuron disease clinical services national institute health care research health technology assessment motor neurone disease association